These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 20489416

  • 1. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ, Lundman P, Tardif JC.
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [Abstract] [Full Text] [Related]

  • 2. Management of dyslipidemia in diabetes.
    Solano MP, Goldberg RB.
    Cardiol Rev; 2006 May; 14(3):125-35. PubMed ID: 16628021
    [Abstract] [Full Text] [Related]

  • 3. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 4. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?].
    Broedl UC, Lehrke M, Parhofer KG.
    MMW Fortschr Med; 2008 Jun 19; 150(25):41-3. PubMed ID: 18705054
    [No Abstract] [Full Text] [Related]

  • 5. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD, Banga JD, Erkelens DW.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):769-74. PubMed ID: 11346913
    [Abstract] [Full Text] [Related]

  • 6. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD.
    Int J Cardiol; 2006 Jun 16; 110(2):137-45. PubMed ID: 16289373
    [Abstract] [Full Text] [Related]

  • 7. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M.
    Dtsch Med Wochenschr; 2009 May 16; 134(20):1067-73. PubMed ID: 19421932
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P, Attvall S, Nilsson PM.
    Lakartidningen; 2009 May 16; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract] [Full Text] [Related]

  • 10. Treating dyslipidemia in the high-risk patient.
    Jones PH.
    J Fam Pract; 2010 Feb 16; 59(2):E1. PubMed ID: 20141719
    [Abstract] [Full Text] [Related]

  • 11. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2].
    Wolffenbuttel BH, Huijberts MS.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):761-5. PubMed ID: 11346911
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

  • 13. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J.
    Am J Med; 2005 Dec 19; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [Abstract] [Full Text] [Related]

  • 14. Lipids for psychiatrists - an overview.
    Young IS.
    J Psychopharmacol; 2005 Nov 19; 19(6 Suppl):66-75. PubMed ID: 16280339
    [Abstract] [Full Text] [Related]

  • 15. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.
    ChemMedChem; 2008 Feb 19; 3(2):206-21. PubMed ID: 17963209
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L, Souchet T, Moulin P, Ritleng C, Desamericq G, Le Jeunne P, Schwalm MS, Van Ganse E.
    Arch Cardiovasc Dis; 2009 Jan 19; 102(1):43-50. PubMed ID: 19233108
    [Abstract] [Full Text] [Related]

  • 18. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ.
    Metab Syndr Relat Disord; 2009 Apr 19; 7(2):83-8. PubMed ID: 19400742
    [Abstract] [Full Text] [Related]

  • 19. [Hypolipidemic drugs and diabetes mellitus].
    Bláha V, Mistrík E.
    Vnitr Lek; 2009 Apr 19; 55(4):357-62. PubMed ID: 19449750
    [Abstract] [Full Text] [Related]

  • 20. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P.
    Am J Cardiol; 2008 Nov 17; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.